You are here: Industry Insights > remestemcel-L

News List

Novartis terminates remestemcel-L development agreement with Mesoblast Pharmaceutical-Technology
December 16, 2021
Novartis has cancelled an agreement to develop, produce and market Mesoblast’s mesenchymal stromal cell (MSC) product remestemcel-L.
Mesoblast’s remestemcel-L lowers mortality in Covid-19 ARDS patients pharmaceutical-technology
May 06, 2021
Mesoblast has reported that results from a trial showed remestemcel-L reduced mortality in ventilator-dependent Covid-19 patients aged below 65 years with moderate/severe acute respiratory distress syndrome (ARDS) through day 60 by 46%.
FDA grants Fast Track designation to COVID-19 ARDS treatment europeanpharmaceuticalreview
December 04, 2020
The designation should expedite the review of remestemcel-L, a cellular therapy that has shown promise in treating acute respiratory distress syndrome (ARDS) in COVID-19 patients.
Mesoblast signs ARDS therapy development deal with Novartis pharmaceutical-technology
November 25, 2020
Mesoblast and Novartis have signed an exclusive agreement for the development, manufacture and commercialisation of the former’s mesenchymal stromal cell (MSC) product remestemcel-L.
Novartis secures rights to Mesoblast’s remestemcel-L for ARDS pharmatimes
November 23, 2020
Swiss pharma Novartis has inked an exclusive licence and collaboration agreement with Mesoblast to develop remestemcel-L for acute respiratory distress syndrome (ARDS), including COVID-19-associated ARDS.
Stem cell therapy trial for COVID-19 patients with ARDS advised to continue europeanpharmaceuticalreview
November 13, 2020
The trial’s independent Data Safety Monitoring Board (DSMB) recommended that the Phase III study evaluating remestemcel-L continue based on the second interim analysis.
First-in-human trial to study remestemcel-L as Crohn’s disease therapy launched europeanpharmaceuticalreview
October 28, 2020
A Phase I clinical trial of remestemcel-L delivered by an endoscope to patients with Crohn’s disease and ulcerative colitis has commenced.
Expanded access for compassionate use of remestemcel-L in COVID-19 infected children europeanpharmaceuticalreview
July 08, 2020
US expands access to remestemcel-L for compassionate use in COVID-19 infected children with complications of multisystem inflammatory syndrome.